Parulian Simanjuntak, Executive Director at IPMG, explains the crucial role that MNCs should play within Indonesian universal healthcare coverage (JKN) and discusses the future challenges that should be addressed to enhance the national healthcare system.
Indonesia is one of the strongest pharmaceutical markets within the region. Valued at USD 5.5 billion, the market has an incredible 12.6 percent annual growth, which is expected to be maintained in 2018 as well as reaching USD 12 billion value by 2020. What are the steps that the international pharmaceutical industry should undertake in order to capitalize on this growth?
"Even though government policy is mainly cost-driven, we strongly believe that the national healthcare system and the Indonesian patients’ quality of life can be enhanced if MNCs participate in this governmental program with their innovative products."
